I was dangling upside down from my monitor stand yesterday, staring at a chart that looked like a banana peel someone had stepped on—all crumpled and unpredictable. The stock in question? Editas Medicine (EDIT), and let me tell you, watching it bounce around has been like watching a monkey (no relation) try to negotiate with a fruit vendor who doesn’t speak primate.
Here’s the thing: I don’t usually get excited about companies losing money. I’m a market analyst, not a motivational speaker. But Editas isn’t your typical money-pit biotech play. This is a company literally rewriting the genetic code of how we treat disease, and right now—right now—they’re at an inflection point that could make early believers look like geniuses or devastate patient accounts like a hurricane through a banana plantation.
Let me back up. Editas Medicine is Cambridge-based, founded in 2013, and they’re riding the CRISPR wave harder than anyone who isn’t Jennifer Doudna herself. CRISPR—clustered regularly interspaced short palindromic repeats, for those keeping score at home—is essentially molecular scissors. Gene-editing scissors. And Editas is trying to use them to cut out disease at the source.
Their lead program, EDIT-401, is targeting hyperlipidemia (high cholesterol) as a one-time therapy. Not a daily pill. Not a quarterly injection. One time. You understand what that means? If this works, you’re looking at a therapy that could capture massive market share in a disease space where millions of people are currently on statins forever. The market size for that alone is in the tens of billions. I threw a banana at my whiteboard when I realized this.
But let’s talk about what makes me nervous and what makes me think this is actually worth your attention, because both things are true simultaneously.
The Beautiful Disaster Numbers
Editas has a market cap of $313 million. They’re losing money hand over fist: negative free cash flow of $71 million annually, zero profit margin, and a debt-to-equity ratio of 66.3. That last number makes me twitch a little. They’re leveraged like a monkey swinging between two very distant trees, and if one branch breaks, well, you know how that ends.
The stock is trading at $3.20 (as of our research date), and here’s where it gets interesting: it’s up 37.7% in the last 20 days despite the broader biotech sector being absolutely demolished. That’s not luck. That’s capital flowing toward something specific. News came out in March about EDIT-401 targeting year-end human proof-of-concept, and the market is pricing in that this might actually work.
The beta is 2.04. This is a wildly volatile stock. For every 1% move in the broader market, EDIT moves roughly 2%. When biotech gets hot, this thing rips. When sentiment turns, it craters. I’ve seen smoother rides at a banana-themed amusement park.
The short ratio is 5.83, which means there’s serious skepticism baked in. Nearly 6 days of average trading volume is tied up in short positions. Shorts are betting this goes to zero—literally zero. The Motley Fool even ran a piece titled “Is Editas Medicine Going to $0?” (spoiler: I don’t think so, but I understand the concern).
Why This Isn’t a Lottery Ticket (But It’s Close)
Here’s where I need to separate myself from the doomers and the lottery-ticket crowd. Editas isn’t just lab coats with delusions. They have:
A real clinical pathway. EDIT-401 has already moved through early safety and efficacy trials. The fact that they’re targeting year-end proof-of-concept in humans means the lab stuff worked. It moved. Now they’re betting that human biology cooperates, which is always the gamble with gene therapy.
Serious backing. They’ve got a research collaboration with Juno Therapeutics (itself a Celgene subsidiary, so there’s institutional weight behind this). They’re not bootstrapped. They have runway. The cash burn is ugly, but it’s not “we’re dead in 8 months” ugly.
A massive addressable market. Hyperlipidemia affects roughly 100 million Americans. Statins are effective but compliance is awful and side effects are real. A one-time gene therapy that could reduce LDL cholesterol permanently? That’s not niche. That’s transformational. Even if Editas captures 5% of that market, you’re talking about billions in revenue.
The thesis is: if EDIT-401 hits proof-of-concept this year and shows the kind of efficacy the market is dreaming about, this stock won’t be at $3.20 in two years. It’ll be substantially higher. If it fails or has safety issues, it probably goes below $1. That’s the bet.
The Risks That Keep Me Awake (Besides My Nocturnal Primate Lifestyle)
Gene therapy is hard. I can’t stress this enough. There are graveyards of biotech companies that had brilliant science and couldn’t translate it into human efficacy. Immune responses, off-target editing, delivery challenges—these aren’t theoretical problems. They’re things that kill programs.
EDIT’s debt load is concerning. That 66.3 debt-to-equity ratio means if they need to raise capital before hitting a revenue inflection point, dilution is coming. Existing shareholders get watered down. It’s not catastrophic—biotech companies do this all the time—but it’s a headwind.
The regulatory path for gene therapy is also… let’s call it “uncertain.” The FDA is still writing the playbook here. What looks approvable today might hit unexpected regulatory friction tomorrow. The goalpost moves.
And the broader biotech sector volatility means that even if Editas hits all their milestones, a sector-wide selloff could drag them down anyway. They’re a small ship in a stormy sea.
Why I’m Nudging This One Forward Anyway
Look, I don’t recommend high-risk biotech stocks to people who need their money for a house down payment. But for portfolios with real risk tolerance and a 3-5 year time horizon? This is the kind of asymmetric bet that makes sense occasionally.
The momentum is real. The science is legitimate. The market size is massive. And they’re right at the clinical inflection point where data matters more than hype. We’re weeks or months away from knowing whether their lead program actually works in humans. That’s the moment everything changes.
The analyst consensus target is $5.72, and Foxy’s pushing for $7.50. That’s 135-240% upside from current levels. Yes, that includes the possibility of catastrophic downside, but the risk-reward ratio here actually favors the upside takers—if you can stomach the volatility.
I’m not saying EDIT is a sure thing. I’m saying it’s the kind of bet where if you get it right, you’re significantly richer, and if you get it wrong, you knew the risks. That’s not gambling. That’s investing.
Maurice adjusts his tiny blazer and grabs another banana. “The scissors work, or they don’t,” he mutters. “But at these prices, the upside tells a compelling story.”
Trained Market Monkey 